Study on Sacituzumab Tirumotecan Treatment Compared to Standard Care for Recurrent Ovarian Cancer

Inclusion Criteria

• Diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Completed at least 4 cycles of platinum-based chemotherapy initially and 6 cycles of carboplatin-based chemotherapy in the second round of treatment.
• Cancer is sensitive to platinum-based treatments.
• Provided a sample of tumor tissue that hasn't been treated with radiation.
• If HIV-positive, must have well-controlled HIV with medication.
• If hepatitis B positive, must have been on antiviral treatment for at least 4 weeks and have no detectable virus before starting the study.
• If previously infected with hepatitis C, must have no detectable virus at screening.
• Must be in good general health with an ECOG performance status of 0 or 1.

Exclusion Criteria

• Have types of ovarian cancer that are not epithelial, such as germ cell tumors or sex cord-stromal tumors.
• Have ovarian cancer that does not respond to platinum-based treatments.
• Have severe eye conditions like dry eye syndrome or corneal disease.
• Have active inflammatory bowel disease or a history of it.
• Have serious heart or blood vessel diseases.
• Have lung diseases that required steroid treatment.
• Have HIV with a history of certain related diseases.
• Have had more than 2 previous treatments for ovarian cancer.
• Have had cancer treatments or radiation recently.
• Have another active cancer that needed treatment in the last 3 years.
• Have cancer that has spread to the brain or spinal cord.
• Have an active infection needing treatment.